PGP and in situ carcinoma: In CIS-resistant IGROVCDDP ovarian cancer cell lines with P-gp overexpression, treatment with 0.25 μM elacridar caused increased cell sensitivity to several P-gp substrates (docetaxel, PAC, epirubicin, and vinblastine), though it has not affected resistance to drugs that are not carried by this protein (SN-38, 5-FU, and methotrexate) [37].